Pre-made Clazakizumab benchmark antibody ( Whole mAb, anti-IL6 therapeutic antibody, Anti-BSF-2/BSF2/CDF/HGF/HSF/IFN-beta-2/IFNB2/IL-6 Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-110
Pre-Made Clazakizumab biosimilar, Whole mAb, Anti-IL6 Antibody: Anti-BSF-2/BSF2/CDF/HGF/HSF/IFN-beta-2/IFNB2/IL-6 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Clazakizumab (formerly ALD518 and BMS-945429), an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6. Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Clazakizumab biosimilar, Whole mAb, Anti-IL6 Antibody: Anti-BSF-2/BSF2/CDF/HGF/HSF/IFN-beta-2/IFNB2/IL-6 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Alder Biopharmaceuticals;Cedars-Sinai Medical Center;Medical University of Vienna;Vitaeris|
|Conditions Active||Renal transplant rejection;COVID-19|
|Conditions Discontinued||Anaemia;Cachexia;Fatigue;Stomatitis;Crohn's disease;Graft-versus-host disease;Inflammation;Psoriatic arthritis;Rheumatoid Arthritis|